We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Determination of Optimum Duration of Treatment With Bromfenac (Xibrom) Eyedrops Following Cataract Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00758199
Recruitment Status : Completed
First Posted : September 25, 2008
Last Update Posted : March 15, 2012
Information provided by (Responsible Party):
Bp Consulting, Inc

September 22, 2008
September 25, 2008
March 15, 2012
July 2008
January 2010   (Final data collection date for primary outcome measure)
OCT with macular thickening [ Time Frame: 3-6 weeks ]
Same as current
Complete list of historical versions of study NCT00758199 on ClinicalTrials.gov Archive Site
Incidence of CME [ Time Frame: 3-6 weeks ]
Same as current
Not Provided
Not Provided
Determination of Optimum Duration of Treatment With Bromfenac (Xibrom) Eyedrops Following Cataract Surgery
Determination of Optimum Duration of Treatment With Bromfenac (Xibrom) Eyedrops Following Cataract Surgery
The objective of this study is to determine if an extension of bromfenac BID monotherapy is effective in the decreasing retinal thickening post cataract IOL placement surgery. No studies exist on how long to treat with an NSAID post cataract IOL placement surgery. Currently, NSAID therapy post IOL placement surgery is in conjunction with steroid treatment, lasting approximately 3 weeks. This study is designed to examine if there is benefit to extending NSAID monotherapy in regards to macular thickening and the incidence of CME.
Not Provided
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Investigator)
Primary Purpose: Treatment
  • Drug: Bromfenac
    Group 1: Bromfenac BID for 3 weeks Group 2: Bromfenac BID for 6 weeks
    Other Name: Bromfenac (Xibrom)
  • Drug: Moxifloxacin hydrochloride
    Group 1 and Group 2:Moxifloxacin hydrochloride 1 day prior to surgery-continue for six days after surgery.
    Other Name: Moxifloxacin hydrochloride (Vigamox)
  • Drug: Prednisolone Acetate
    Group 1 and Group 2:Prednisolone Acetate for 3 weeks in a tapering schedule (week 1: TID; week 2: BID, week 3:QD).
    Other Name: Omni-Pred
  • Active Comparator: 2
    Intervention: Drug: Moxifloxacin hydrochloride
  • Placebo Comparator: 3
    Prednisolone Acetate
    Intervention: Drug: Prednisolone Acetate
  • Active Comparator: 1
    Intervention: Drug: Bromfenac
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
January 2010
January 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or female >18 years of age scheduled to undergo bilateral cataract surgery
  • Patients with systemic diseases will be enrolled only if there are no ocular manifestations of their disease (e.g. diabetics with normal retinal exams)
  • Expected visual outcome of BCVA > [greater than or equal to] 20/30 postoperatively
  • Ability to provide informed consent, take study medications as directed, and likely to complete all study visits

Exclusion Criteria:

  • Known contraindication to any study medication or any of their components
  • Required use of ocular medications other than the study medications during the study
  • Significant AMD, epi-retinal membrane, retinal vein occlusion, diabetic macular edema, or any macular disease predisposing them to cystoid macular edema.
  • Posterior capsule rupture, Vitreous loss during surgery or any other complication that in the surgeon's opinion, could reduce potential for targeted visual outcome
  • Anticipated need for mechanical iris dilating devices
Sexes Eligible for Study: All
18 Years to 80 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Bp Consulting, Inc
Bp Consulting, Inc
Not Provided
Not Provided
Bp Consulting, Inc
March 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP